Bronchoalveolar carcinoma: Difference between revisions

Jump to navigation Jump to search
 
(14 intermediate revisions by 3 users not shown)
Line 3: Line 3:
{{CMG}} '''Associate Editor-in-Chief:''' [https://www.wikidoc.org/index.php/User%3AK.Nouman <nowiki>Khuram Nouman, M.D. [2]</nowiki>]
{{CMG}} '''Associate Editor-in-Chief:''' [https://www.wikidoc.org/index.php/User%3AK.Nouman <nowiki>Khuram Nouman, M.D. [2]</nowiki>]
==Overview==
==Overview==
* [[Lung cancer]] the leading cause of cancer related death in the world.
[[Lung cancer]] the leading cause of cancer related death in the world. Bronchoalveolar carcinoma (BAC) was first described by Malassez in 1876 as a bilateral,multinodular malignant [[pulmonary carcinoma]]. " Bronchoalveolar cell carcinoma" term was first coined by Leibow in 1960 due to confusion over cell type. BAC was use as a term in 1999 and 2004 WHO classification for a broad range of [[Tumor|tumors]] including single small [[non-invasive peripheral lung tumor]], minimally invasive adenocarcinoma, mixed subtype invasive adenocarcinoma, mucinous and nonmucinous subtypes that are previously known as BAC and advanced type with invasion and poor prognosis. The 1999 WHO classification was largely based on histologic characteristics, the 2004 revised classification in addition to  histological factors  took other factors like genetic and clinical factors into consideration but these two classification continue to use the term BAC. Later, in 2011 IASLC in collaboration with other lung societies introduced a new classification based on multidisciplinary approach to avoid the confusion related to use of BAC for broad range of tumors. Bronchoalveolar carcinoma is a preinvasive carcinoma with no [[Stromal cell|stromal]],[[vascular]] and [[pleural invasion]]. Adenocarcinoma in situ, minimally invasive adenocarcinoma and invasive adenocarcinoma of the lung are the relatively new terms that were introduced in 2011 [[IASLC/ATS/ERS classifications]] for [[bronchoalveolar carcinoma]] (BAC). BAC is usually asymptomatic but may present with [[cough]], [[hemoptysis]], [[Chest pain, cough and dyspnea|chest pain]], [[loss of appetite]] and [[weight loss]]. It is a rare pulmonary tumor and the incidence for BAC varies from 4-24% of all the primary lung malignancies. Surgery is the mainstay of treatment but mucinous type respond very well to [[List of chemotherapy regimens|chemotherapy]] because of genetic associations. The five year survival rate for surgically resected tumor is 100%.
* Bronchoalveolar carcinoma (BAC) was first described by Malassez in 1876 as a bilateral,multinodular malignant [[pulmonary carcinoma]]. " Bronchoalveolar cell carcinoma" term was first coined by Leibow in 1960 due to confusion over cell type.
* BAC was use as a term in 1999 and 2004 WHO classification for a broad range of [[Tumor|tumors]] including single small [[non-invasive peripheral lung tumor]], minimally invasive adenocarcinoma, mixed subtype invasive adenocarcinoma, mucinous and nonmucinous subtypes that are previously known as BAC and advanced type with invasion and poor prognosis.  
* The 1999 WHO classification was largely based on histologic characteristics, the 2004 revised classification in addition to  histological factors  took other factors like genetic and clinical factors into consideration but these two classification continue to use the term BAC.
* Later, in 2011 IASLC in collaboration with other lung societies introduced a new classification based on multidisciplinary approach to avoid the confusion related to use of BAC for broad range of tumors. Bronchoalveolar carcinoma is a preinvasive carcinoma with no [[Stromal cell|stromal]],[[vascular]] and [[pleural invasion]].
* [[Adenocarcinoma in situ]], [[minimally invasive adenocarcinoma]] and [[invasive adenocarcinoma]] of the lung are the relatively new terms that were introduced in 2011 [[IASLC/ATS/ERS classifications]] for [[bronchoalveolar carcinoma]] (BAC).
* BAC is usually asymptomatic but may present with [[cough]], [[hemoptysis]], [[Chest pain, cough and dyspnea|chest pain]], [[loss of appetite]] and [[weight loss]].
* It is a rare pulmonary tumor and the incidence for BAC varies from 4-24% of all the primary lung malignancies.
* Surgery is the mainstay of treatment but mucinous type respond very well to [[List of chemotherapy regimens|chemotherapy]] because of genetic associations.
* The five year survival rate for surgically resected tumor is 100%.


==Historical Perspective==
==Historical Perspective==
*Bronchoalveolar Carcinoma was first described by Malassez in 1876 as a bilateral, multinodular type of malignant lung carcinoma.
*Bronchoalveolar Carcinoma was first described by Malassez in 1876 as a bilateral, multinodular type of malignant lung carcinoma.
*The term "Bronchoalveolar cell carcinoma" was first introduced by Liebow in 1960 due to confusion over true cell type.It comes from two cell types. [[Columnar epithelia|columnar epithelium]] similar to [[bronchial cells]] and [[Cuboidal epithelia|cuboidal]] type reminiscent of type 2 pneumocytes.  
*The term "Bronchoalveolar cell carcinoma" was first introduced by Liebow in 1960 due to confusion over true cell type.It comes from two cell types. [[Columnar epithelia|columnar epithelium]] similar to [[bronchial cells]] and [[Cuboidal epithelia|cuboidal]] type reminiscent of type 2 pneumocytes.  
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
   
   
==Classification==
==Classification==
*Bronchoalveolar Carcinoma may be classified according to pathology into fo subtypes/groups:
*Bronchoalveolar Carcinoma may be classified according to pathology into fo subtypes/groups:
*'''Pathology of lung adenocarcinomas according to previous 2004 WHO and current IASLC/ATS/ERS classifications'''<ref>{{cite journal|doi=10.3978/j.issn.2072-1439.2014.01.27}}</ref>
'''Pathology of lung adenocarcinomas according to previous 2004 WHO and current IASLC/ATS/ERS classifications'''
{| class="wikitable"
{| class="wikitable"
| colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |2004 WHO classification
| colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |2004 WHO classification
Line 28: Line 17:
| colspan="1" rowspan="1" |    Mixed subtype
| colspan="1" rowspan="1" |    Mixed subtype
|-
|-
| colspan="1" rowspan="1" |    Acinar
| colspan="1" rowspan="1" |    [[Acinar]]
|-
|-
| colspan="1" rowspan="1" |    Papillary
| colspan="1" rowspan="1" |    [[Papillary]]
|-
|-
| colspan="1" rowspan="1" |    BAC
| colspan="1" rowspan="1" |    BAC
|-
|-
| colspan="1" rowspan="1" |         Non mucinous
| colspan="1" rowspan="1" |         [[Non mucinous]]
|-
|-
| colspan="1" rowspan="1" |         Mucinous
| colspan="1" rowspan="1" |         [[Mucinous]]
|-
|-
| colspan="1" rowspan="1" |         Mixed
| colspan="1" rowspan="1" |         Mixed
Line 42: Line 31:
| colspan="1" rowspan="1" |    Solid adenocarcinoma
| colspan="1" rowspan="1" |    Solid adenocarcinoma
|-
|-
| colspan="1" rowspan="1" |         Colloid
| colspan="1" rowspan="1" |         [[Colloid]]
|-
|-
| colspan="1" rowspan="1" |         Fetal
| colspan="1" rowspan="1" |         [[Fetal]]
|-
|-
| colspan="1" rowspan="1" |         Mucinous cystadenocarcinoma
| colspan="1" rowspan="1" |         [[Mucinous cystadenocarcinoma]]
|-
|-
| colspan="1" rowspan="1" |         Signet-ring
| colspan="1" rowspan="1" |         [[Signet-ring]]
|-
|-
| colspan="1" rowspan="1" |         Clear-cell
| colspan="1" rowspan="1" |         [[Clear-cell]]
|-
|-
| colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Major changes in the new IASLC/ATS/ERS classification
| colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Major changes in the new IASLC/ATS/ERS classification
Line 62: Line 51:
| colspan="1" rowspan="1" |    Introduction of AIS and MIA as new entities
| colspan="1" rowspan="1" |    Introduction of AIS and MIA as new entities
|-
|-
| colspan="1" rowspan="1" |    Introduction of micropapillary adenocarcinoma as a predominant subtype
| colspan="1" rowspan="1" |    Introduction of [[micropapillary adenocarcinoma]] as a predominant subtype
|-
|-
| colspan="1" rowspan="1" |    Introduction of lepidic predominant adenocarcinoma and lepidic growth as new terminologies
| colspan="1" rowspan="1" |    Introduction of lepidic predominant adenocarcinoma and [[lepidic growth]] as new terminologies
|-
|-
| colspan="1" rowspan="1" |    Exclusion of signet-ring and clear cell adenocarcinomas
| colspan="1" rowspan="1" |    Exclusion of signet-ring and clear cell adenocarcinomas
Line 76: Line 65:
| colspan="1" rowspan="1" |    AIS
| colspan="1" rowspan="1" |    AIS
|-
|-
| colspan="1" rowspan="1" |         Non-mucinous
| colspan="1" rowspan="1" |         [[Non-mucinous]]
|-
|-
| colspan="1" rowspan="1" |         Mucinous
| colspan="1" rowspan="1" |         [[Mucinous]]
|-
|-
| colspan="1" rowspan="1" |         Mixed
| colspan="1" rowspan="1" |         Mixed
Line 86: Line 75:
| colspan="1" rowspan="1" |         Non-mucinous
| colspan="1" rowspan="1" |         Non-mucinous
|-
|-
| colspan="1" rowspan="1" |         Mucinous
| colspan="1" rowspan="1" |         [[Mucinous]]
|-
|-
| colspan="1" rowspan="1" |         Mixed
| colspan="1" rowspan="1" |         Mixed
Line 96: Line 85:
| colspan="1" rowspan="1" |         Acinar predominant
| colspan="1" rowspan="1" |         Acinar predominant
|-
|-
| colspan="1" rowspan="1" |         Papillary predominant
| colspan="1" rowspan="1" |       [[Apillary predominant| Papillary predominant]]
|-
|-
| colspan="1" rowspan="1" |         Micropapillary predominant
| colspan="1" rowspan="1" |         [[Micropapillary predominant]]
|-
|-
| colspan="1" rowspan="1" |         Solid predominant with mucin production
| colspan="1" rowspan="1" |         Solid predominant with mucin production
Line 108: Line 97:
| colspan="1" rowspan="1" |         Colloid
| colspan="1" rowspan="1" |         Colloid
|-
|-
| colspan="1" rowspan="1" |         Fetal
| colspan="1" rowspan="1" |         [[Fetal]]
|-
|-
| colspan="1" rowspan="1" |         Enteric
| colspan="1" rowspan="1" |         [[Enteric]]
|}
|}


WHO, World Health Organization; IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; BAC, bronchioloalveolar carcinoma; AIS, adenocarcinoma ''in situ''; MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous adenocarcinoma.
<small> WHO, World Health Organization; IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; BAC, bronchioloalveolar carcinoma; AIS, adenocarcinoma ''in situ''; MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous adenocarcinoma. </small>


==Pathology==
==Pathophysiology==
*In 2011, the term bronchoalveolar carcinoma is discontinued and new terms adenocarcinoma in situ and minimally invasive adenocarcinoma replaced the term BAC,
*In 2011, the term bronchoalveolar carcinoma is discontinued and new terms [[adenocarcinoma in situ]] and minimally invasive adenocarcinoma replaced the term BAC,
{| class="wikitable"
{| class="wikitable"
|+style="background:#4479BA; color: #FFFFFF;" align="center"
|+
!Type
! style="background:#4479BA; color: #FFFFFF;" align="center" |Type
!Subtypes
! style="background:#4479BA; color: #FFFFFF;" align="center" |Subtypes
!Cell Type
! style="background:#4479BA; color: #FFFFFF;" align="center" |Cell Type
!Comments
! style="background:#4479BA; color: #FFFFFF;" align="center" |Comments
|-
|-
![[Adenocarcinoma in Situ]]
|
|
* Adenocarcinoma in Situ
* [[Non Mucinous]]
|
* [[Mucinous]]
* Non Mucinous
* Mucinous
* Mixed
* Mixed
|
|
Line 134: Line 122:
* type II pneumocytes and/or Clara cells
* type II pneumocytes and/or Clara cells
Mucinous:
Mucinous:
* tall columnar cells with basal nuclei
* tall [[columnar cells]] with basal nuclei
* abundant cytoplasmic mucin
* abundant cytoplasmic mucin
|
|
Line 141: Line 129:
* pure lepidic growth  
* pure lepidic growth  
* Well circumscribed  
* Well circumscribed  
* No stromal, vascular or pleural invasion.
* No [[stromal]], [[vascular]] or [[pleural invasion]].
|-
|-
|
![[Minimally Invasive Adenocarcinoma]]
* Minimally Invasive Adenocarcinoma
|
|
* Non Mucinous
* Non Mucinous
* Mucinous
* [[Mucinous]]
|
|
* Non-Mucinous
* Non-Mucinous
* Mucinous
* [[Mucinous]]
|
|
* lepidic pattern
* lepidic pattern
Line 156: Line 143:
* < 5 mm invasion  
* < 5 mm invasion  
|}
|}
 
*
==Clinical Features== 


==Differentiating Bronchoalveolar carcinoma from other Diseases==
==Differentiating Bronchoalveolar carcinoma from other Diseases==
*BAC must be differentiated from other diseases that cause cough, hemoptysis, and solitary nodule on X-Ray such as:
*BAC must be differentiated from other diseases that cause cough, hemoptysis, and solitary nodule on X-Ray such as:
:*Malignant and benign lesion
:*Malignant and benign lesion
:*Inflammatory
:*Infection e.g pulmonary [[Tuberculosis, pulmonary|tuberculosis]]
:*Congenital
:*Congenital
:*miscellaneous
:*Miscellaneous e.g [[Wegener's granulomatosis|Wegener]] and [[lymphomatoid granulomatosis]]
   
   
==Epidemiology and Demographics==
==Epidemiology and Demographics==
* Bronchoalveolar carcinoma is  a rare tumor, the incidence of BAC vary from 4-24% of all the primary lung malignancies. More newer studies suggest [[Adenocarcinoma in situ]] and minimally invasive carcinoma constitutes 2-14% of all the primary types of lung cancers.
* Bronchoalveolar carcinoma is  a rare tumor, the incidence of BAC vary from 4-24% of all the primary lung malignancies. More newer studies suggest [[Adenocarcinoma]] in situ and minimally invasive carcinoma constitutes 2-14% of all the primary types of lung cancers.
   
   
===Age===
===Age===
Line 177: Line 163:
*Bronchoalveolar Carcinoma affects men and women disproportionately.
*Bronchoalveolar Carcinoma affects men and women disproportionately.
   
   
*Women are more commonly affected with bronchoalveolar carcinoma than men.
*Women are more commonly affected with bronchoalveolar [[carcinoma]] than men.
   
   
===Race===
===Race===
Line 183: Line 169:
   
   
==Risk Factors==
==Risk Factors==
*Common risk factors in the development of BAC are Asian race, women gender, and pulmonary fibrosis.
*Common risk factors in the development of BAC are Asian race, women gender, and [[pulmonary fibrosis]].
== Lung cancer Screening ==
The U.S. Preventive Services Task Force recommends annual [[lung cancer]] screening with low density [[Computed tomography|CT Scan]] for people who has history of,
* Have a 30 pack per year or more smoking history, '''''and'''''
* Current smoker or left smoking within the past 15 years, '''''and'''''
* Are aged between 55 and 80 years old.
== Natural History, Complications and Prognosis==
== Natural History, Complications and Prognosis==
*The majority of patients with [disease name] remain asymptomatic for [duration/years].  
*The majority of patients with BAC remain asymptomatic for many years.  
*Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
*Late clinical features include [[cough]], [[mucus production]], and persistent [[chest pain.]]
*If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
*If left untreated,patients with BAC may progress to invasive adenocarcinoma.
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Prognosis is generally good, and the 5 survival rate of patients with BAC is approximately.
*Prognosis is generally good, and the 5 survival rate of patients with BAC is approximately  
*Prognosis of BAC depends on the histologic type. Non-mucinous AIS has better prognosis than [[mucinous]] type AIS.  
*Prognosis of BAC depends on the histologic type. Non-mucinous AIS has better prognosis than mucinous type AIS.  
*Mixed type has far worse survival rate than either of the [[monophasic]] form.  
*Mixed type has far worse survival rate than either of the monophasic form.  


== Diagnosis ==
== Diagnosis ==
=== Clinical Features ===
Bronchoalveolar carcinoma is usually asymptomatic and takes a very long time before becoming symptomatic. BAC may cause large quantities of mucus production, patients may present with bronchorrhea.
Solitary pulmonary nodule on Chest X-Ray that does not resolve despite taking antimicrobial therapy should be evaluated further for BAC.
CT or guided biopsy should be done in such cases. to reach the definite diagnosis.
===Diagnostic Criteria===
===Diagnostic Criteria===
*The diagnostic criteria for bronchoalveolar carcinoma have changed over time.According to new 2011 IASLC/ATS recommendations, adopted in the 2015 WHO guidelines, use the following criteria for bronchoalveolar carcinoma
*The diagnostic criteria for bronchoalveolar carcinoma have changed over time. According to new 2011 IASLC/ATS recommendations, adopted in the 2015 WHO guidelines, use the following criteria for bronchoalveolar carcinoma
:*Localized small tumor < 3 cm
:*Localized small tumor < 3 cm
:*pure "[[lepidic growth]]"
:*pure "[[lepidic growth]]"
:*No stromal, vascular or pleural invasion
:*No [[stromal]], [[vascular]] or [[pleural]] invasion
:*[[Nuclear atypia]] absent/minimal in both mucinous/non-mucinous AIS
:*[[Nuclear atypia]] absent/minimal in both mucinous/non-mucinous AIS
:*[[Septal broadening]] with sclerosis (non-mucinous type)
:*[[Septal broadening]] with [[sclerosis]] (non-mucinous type)
:*No spread through air spaces
:*No spread through air spaces
   
   
Line 219: Line 216:
*Patients with BAC usually appear  
*Patients with BAC usually appear  
*Physical examination may be remarkable for:
*Physical examination may be remarkable for:
:*low grade fever
:*[[Low-grade fever|Low grade fever]]
:*Cachexia  
:*[[Cachexia]]
:*bronchorrhea   
:*[[bronchorrhea]]  
:*Other signs like dyspnea, pleural effusion and enlargement of lymph nodes can occur in advanced stage disease.
:*Other signs like [[dyspnea]], [[Pleural effusion|pleura]]<nowiki/>l effusion and enlargement of [[lymph nodes]] can occur in advanced stage disease.


=== Laboratory Findings ===
=== Laboratory Findings ===
Line 231: Line 228:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Comments
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Comments
|-
|-
|CBC
![[Complete blood count|CBC]]
|To rule out neutropenic fever in patients taking chemotherapy.
|To rule out [[neutropenic fever]] in patients taking [[chemotherapy]].
|-
|-
|Liver function test (LFTs)
!Liver function test (LFTs)
|Insignificant except in advanced disease.
|Insignificant except in advanced disease.
|-
|-
|Serum electrolytes
![[Electrolyte|Serum electrolytes]]
|To check for hyponatremia to rule out SIADH
|To check for hyponatremia to rule out [[SIADH]]
|-
|-
|Arterial Blood Gases (ABGs)
!Arterial Blood Gases (ABGs)
|To detect respiratory failure in sick patient.
|To detect [[respiratory failure]] in sick patient.
|-
|-
|Serum Calcium
!Serum [[Calcium]]
|Hypercalcemia can occur due to Parathyroid hormone related protein (PTH-rP)
|[[Hypercalcemia]] can occur due to Parathyroid hormone related protein (PTH-rP)
|-
|-
|Serum PTH
!Serum [[PTH]]
|To check for cause of hypercalcemia. It helps to differentiate whether the high calcium level is due to hyperparathyroidism or paraneoplastic syndrome (PTH-rP)
|To check for cause of [[hypercalcemia]]. It helps to differentiate whether the high calcium level is due to [[hyperparathyroidism]] or [[paraneoplastic syndrome]] (PTH-rP)
|}
|}


===Imaging Findings===
===Imaging Findings===
*There are three radiologic findings associated with bronchoalveolar carcinoma are,
*There are three radiologic findings associated with bronchoalveolar carcinoma are:
**[[Solitary nodule]]- most common
**[[Solitary nodule]]- most common
**[[Consolidation (medicine)|Consolidation]]
**[[Consolidation (medicine)|Consolidation]]
**[[multinodular opacities]]
**Multinodular opacities
   
   
*The nodular form is the commonest and can not be differentiated from other adenocarcinoma subtypes on plain X-ray.
*The [[nodular]] form is the commonest and can not be differentiated from other adenocarcinoma subtypes on plain X-ray.
*[[CT scan]] is imaging modality of the choice for bronchoalveolar carcinoma.
*[[CT scan]] is imaging modality of the choice for bronchoalveolar carcinoma.
**Non-Mucinous BAC: It appears as solid nodule surrounded by ground glass opacification- [[Fried egg sign]]
**Non-Mucinous BAC: It appears as solid nodule surrounded by ground glass opacification- [[Fried egg sign]]
**Mucinous BAC: It appears as single solid nodule.
**Mucinous BAC: It appears as single solid nodule
 
'''Bronchoalveolar carcinoma CT scan'''
*Subtype of adenocarcinoma<ref name="GandaraAberle2006">{{cite journal|last1=Gandara|first1=David R.|last2=Aberle|first2=Denise|last3=Lau|first3=Derick|last4=Jett|first4=James|last5=Akhurst|first5=Tim|last6=Mulshine|first6=James|last7=Berg|first7=Christine|last8=Patz|first8=Edward F.|title=Radiographic Imaging of Bronchioloalveolar Carcinoma: Screening, Patterns of Presentation and Response Assessment|journal=Journal of Thoracic Oncology|volume=1|issue=9|year=2006|pages=S20–S26|issn=15560864|doi=10.1016/S1556-0864(15)30005-8}}</ref>
*Single pulmonary nodule or mass
*Multicentric or diffuse disease
*Localized area of parenchymal consolidation
*Bubble-like areas of low attenuation within the mass are a characteristic finding
*[[Hilar lymphadenopathy|Hilar]] and [[mediastinal lymphadenopathy]] is uncommon
*Persistent peripheral [[Lung consolidation|consolidation]] with associated [[Pulmonary nodule|nodules]]


<gallery align="right" mode="packed">
<gallery align="right" mode="packed">
Line 268: Line 274:


=== Other Diagnostic Studies ===
=== Other Diagnostic Studies ===
*BAC may also be differentiated from invasive adenocarcinoma by using magnetic resonance imaging.
*BAC may also be differentiated from invasive adenocarcinoma by using [[magnetic resonance imaging]].
*Image guided per-cutaneous [[fine needle aspiration biopsy]] or [[core biopsy]] can be used to get molecular characteristic of the tumor.
*Image guided per-cutaneous fine needle aspiration biopsy or core biopsy can be used to get molecular characteristic of the tumor.
*[[ECG]] can be done to rule out other causes of chest pain.


== Treatment ==
== Treatment ==
=== Medical Therapy ===
=== Medical Therapy ===
*Non-Mucinous BAC responds well to targeted chemotherapy like epidermal growth factor receptor [[tyrosine kinase inhibitors]] [[erlotinib]] and [[gefitinib.]]
*Non-Mucinous BAC responds well to targeted [[chemotherapy]] like epidermal growth factor receptor [[tyrosine kinase inhibitors]] [[erlotinib]] and [[gefitinib.]]
*Patient with non-resectable tumor can also benefit from [[erlotinib]] and [[gefitinib]] than other subtypes of non small cell lung carcinoma.
*Patient with non-resectable tumor can also benefit from [[erlotinib]] and [[gefitinib]] than other subtypes of [[Non small cell lung cancer|non small cell lung carcinoma]].
*Mucinous BAC are highly associated with [[K-RAS|K-RAS mutation]] and wild-type [[EGFR]] and does not respond well to EGFR [[tyrosine kinase inhibitor]].  
*Mucinous BAC are highly associated with K-RAS mutation and wild-type [[EGFR]] and does not respond well to EGFR [[tyrosine kinase inhibitor]].  
   
   
=== Surgery ===
=== Surgery ===
*Surgery is the mainstay of therapy for bronchoalveolar carcinoma.
*Surgery is the mainstay of therapy for bronchoalveolar carcinoma.
*[[Pneumonectomy]] or [[Lobectomy of lung|lobectomy]] in conjunction with ipsilateral lymphadenectomy is the most common approach to the treatment of BAC.
*[[Pneumonectomy]] or [[Lobectomy of lung|lobectomy]] in conjunction with ipsilateral [[lymphadenectomy]] is the most common approach to the treatment of BAC.
   
   
=== Prevention ===
=== Prevention ===
* Effective measures for the primary prevention of Lung cancer include smoking cessation, avoid passive smoking, and taking precautionary measures to avoid exposure to harmful particles in work places.
* Effective measures for the primary prevention of Lung cancer include smoking cessation, avoid passive smoking, and taking precautionary measures to avoid exposure to harmful particles in work places.


== Lung cancer Screening ==
*  
The U.S. Preventive Services Task Force recommends annual lung cancer screening with low density CT Scan for people who has history of,
* Have a 30 pack per year or more smoking history, '''''and'''''
* Current smoker or left smoking within the past 15 years, '''''and'''''
* Are aged between 55 and 80 years old.


See also, [https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening Lung cancer screening] [https://www.mskcc.org/cancer-care/types/lung/screening/lung-screening-decision-tool Lung Cancer Screening Decision Tool]
See also, [https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening Lung cancer screening] [https://www.mskcc.org/cancer-care/types/lung/screening/lung-screening-decision-tool Lung Cancer Screening Decision Tool]


==References==
==References==
{{Reflist|2}}
<references />
[[Category:Pick One of 28 Approved]]
 
{{WS}}
{{WH}}

Latest revision as of 16:49, 8 January 2019

WikiDoc Resources for Bronchoalveolar carcinoma

Articles

Most recent articles on Bronchoalveolar carcinoma

Most cited articles on Bronchoalveolar carcinoma

Review articles on Bronchoalveolar carcinoma

Articles on Bronchoalveolar carcinoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bronchoalveolar carcinoma

Images of Bronchoalveolar carcinoma

Photos of Bronchoalveolar carcinoma

Podcasts & MP3s on Bronchoalveolar carcinoma

Videos on Bronchoalveolar carcinoma

Evidence Based Medicine

Cochrane Collaboration on Bronchoalveolar carcinoma

Bandolier on Bronchoalveolar carcinoma

TRIP on Bronchoalveolar carcinoma

Clinical Trials

Ongoing Trials on Bronchoalveolar carcinoma at Clinical Trials.gov

Trial results on Bronchoalveolar carcinoma

Clinical Trials on Bronchoalveolar carcinoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bronchoalveolar carcinoma

NICE Guidance on Bronchoalveolar carcinoma

NHS PRODIGY Guidance

FDA on Bronchoalveolar carcinoma

CDC on Bronchoalveolar carcinoma

Books

Books on Bronchoalveolar carcinoma

News

Bronchoalveolar carcinoma in the news

Be alerted to news on Bronchoalveolar carcinoma

News trends on Bronchoalveolar carcinoma

Commentary

Blogs on Bronchoalveolar carcinoma

Definitions

Definitions of Bronchoalveolar carcinoma

Patient Resources / Community

Patient resources on Bronchoalveolar carcinoma

Discussion groups on Bronchoalveolar carcinoma

Patient Handouts on Bronchoalveolar carcinoma

Directions to Hospitals Treating Bronchoalveolar carcinoma

Risk calculators and risk factors for Bronchoalveolar carcinoma

Healthcare Provider Resources

Symptoms of Bronchoalveolar carcinoma

Causes & Risk Factors for Bronchoalveolar carcinoma

Diagnostic studies for Bronchoalveolar carcinoma

Treatment of Bronchoalveolar carcinoma

Continuing Medical Education (CME)

CME Programs on Bronchoalveolar carcinoma

International

Bronchoalveolar carcinoma en Espanol

Bronchoalveolar carcinoma en Francais

Business

Bronchoalveolar carcinoma in the Marketplace

Patents on Bronchoalveolar carcinoma

Experimental / Informatics

List of terms related to Bronchoalveolar carcinoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-in-Chief: Khuram Nouman, M.D. [2]

Overview

Lung cancer the leading cause of cancer related death in the world. Bronchoalveolar carcinoma (BAC) was first described by Malassez in 1876 as a bilateral,multinodular malignant pulmonary carcinoma. " Bronchoalveolar cell carcinoma" term was first coined by Leibow in 1960 due to confusion over cell type. BAC was use as a term in 1999 and 2004 WHO classification for a broad range of tumors including single small non-invasive peripheral lung tumor, minimally invasive adenocarcinoma, mixed subtype invasive adenocarcinoma, mucinous and nonmucinous subtypes that are previously known as BAC and advanced type with invasion and poor prognosis. The 1999 WHO classification was largely based on histologic characteristics, the 2004 revised classification in addition to histological factors took other factors like genetic and clinical factors into consideration but these two classification continue to use the term BAC. Later, in 2011 IASLC in collaboration with other lung societies introduced a new classification based on multidisciplinary approach to avoid the confusion related to use of BAC for broad range of tumors. Bronchoalveolar carcinoma is a preinvasive carcinoma with no stromal,vascular and pleural invasion. Adenocarcinoma in situ, minimally invasive adenocarcinoma and invasive adenocarcinoma of the lung are the relatively new terms that were introduced in 2011 IASLC/ATS/ERS classifications for bronchoalveolar carcinoma (BAC). BAC is usually asymptomatic but may present with cough, hemoptysis, chest pain, loss of appetite and weight loss. It is a rare pulmonary tumor and the incidence for BAC varies from 4-24% of all the primary lung malignancies. Surgery is the mainstay of treatment but mucinous type respond very well to chemotherapy because of genetic associations. The five year survival rate for surgically resected tumor is 100%.

Historical Perspective

  • Bronchoalveolar Carcinoma was first described by Malassez in 1876 as a bilateral, multinodular type of malignant lung carcinoma.
  • The term "Bronchoalveolar cell carcinoma" was first introduced by Liebow in 1960 due to confusion over true cell type.It comes from two cell types. columnar epithelium similar to bronchial cells and cuboidal type reminiscent of type 2 pneumocytes.

Classification

  • Bronchoalveolar Carcinoma may be classified according to pathology into fo subtypes/groups:

Pathology of lung adenocarcinomas according to previous 2004 WHO and current IASLC/ATS/ERS classifications

2004 WHO classification
    Mixed subtype
    Acinar
    Papillary
    BAC
         Non mucinous
         Mucinous
         Mixed
    Solid adenocarcinoma
         Colloid
         Fetal
         Mucinous cystadenocarcinoma
         Signet-ring
         Clear-cell
Major changes in the new IASLC/ATS/ERS classification
    Discontinuation of the term BAC
    Discontinuation of the mixed subtype
    Comprehensive pathologic subtyping in 5% increments and classification of adenocarcinomas according to the predominant subtype
    Introduction of AIS and MIA as new entities
    Introduction of micropapillary adenocarcinoma as a predominant subtype
    Introduction of lepidic predominant adenocarcinoma and lepidic growth as new terminologies
    Exclusion of signet-ring and clear cell adenocarcinomas
IASLC/ATS/ERS classification
    Pre-invasive lesions
    Atypical adenomatous hyperplasia
    AIS
         Non-mucinous
         Mucinous
         Mixed
    MIA
         Non-mucinous
         Mucinous
         Mixed
    Invasive adenocarcinomas
         Lepidic predominant
         Acinar predominant
        Papillary predominant
         Micropapillary predominant
         Solid predominant with mucin production
    Variants of invasive adenocarcinomas
         IMA
         Colloid
         Fetal
         Enteric

WHO, World Health Organization; IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; BAC, bronchioloalveolar carcinoma; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous adenocarcinoma.

Pathophysiology

  • In 2011, the term bronchoalveolar carcinoma is discontinued and new terms adenocarcinoma in situ and minimally invasive adenocarcinoma replaced the term BAC,
Type Subtypes Cell Type Comments
Adenocarcinoma in Situ

Non-Mucinous:

  • type II pneumocytes and/or Clara cells

Mucinous:

Minimally Invasive Adenocarcinoma
  • lepidic pattern
  • Small size < 3 cm
  • < 5 mm invasion

Differentiating Bronchoalveolar carcinoma from other Diseases

  • BAC must be differentiated from other diseases that cause cough, hemoptysis, and solitary nodule on X-Ray such as:

Epidemiology and Demographics

  • Bronchoalveolar carcinoma is a rare tumor, the incidence of BAC vary from 4-24% of all the primary lung malignancies. More newer studies suggest Adenocarcinoma in situ and minimally invasive carcinoma constitutes 2-14% of all the primary types of lung cancers.

Age

  • Patients of all age groups may develop BAC.
  • BAC is more commonly observed among patients of middle aged group.

Gender

  • Bronchoalveolar Carcinoma affects men and women disproportionately.
  • Women are more commonly affected with bronchoalveolar carcinoma than men.

Race

  • Bronchoalveolar Carcinoma usually affects individuals of the Asian race.

Risk Factors

  • Common risk factors in the development of BAC are Asian race, women gender, and pulmonary fibrosis.

Lung cancer Screening

The U.S. Preventive Services Task Force recommends annual lung cancer screening with low density CT Scan for people who has history of,

  • Have a 30 pack per year or more smoking history, and
  • Current smoker or left smoking within the past 15 years, and
  • Are aged between 55 and 80 years old.

Natural History, Complications and Prognosis

  • The majority of patients with BAC remain asymptomatic for many years.
  • Late clinical features include cough, mucus production, and persistent chest pain.
  • If left untreated,patients with BAC may progress to invasive adenocarcinoma.
  • Prognosis is generally good, and the 5 survival rate of patients with BAC is approximately.
  • Prognosis of BAC depends on the histologic type. Non-mucinous AIS has better prognosis than mucinous type AIS.
  • Mixed type has far worse survival rate than either of the monophasic form.

Diagnosis

Clinical Features

Bronchoalveolar carcinoma is usually asymptomatic and takes a very long time before becoming symptomatic. BAC may cause large quantities of mucus production, patients may present with bronchorrhea.

Solitary pulmonary nodule on Chest X-Ray that does not resolve despite taking antimicrobial therapy should be evaluated further for BAC.

CT or guided biopsy should be done in such cases. to reach the definite diagnosis.

Diagnostic Criteria

  • The diagnostic criteria for bronchoalveolar carcinoma have changed over time. According to new 2011 IASLC/ATS recommendations, adopted in the 2015 WHO guidelines, use the following criteria for bronchoalveolar carcinoma

Symptoms

  • Bronchoalveolar carcinoma is usually asymptomatic because presence of symptoms are usually an indication of an advanced disease.
  • Symptoms of BAC may include the following:

Physical Examination

  • Patients with BAC usually appear
  • Physical examination may be remarkable for:

Laboratory Findings

  • There are no specific laboratory findings associated with BAC. But, these lab findings can be helpful in patients with advanced diseases,
Test Comments
CBC To rule out neutropenic fever in patients taking chemotherapy.
Liver function test (LFTs) Insignificant except in advanced disease.
Serum electrolytes To check for hyponatremia to rule out SIADH
Arterial Blood Gases (ABGs) To detect respiratory failure in sick patient.
Serum Calcium Hypercalcemia can occur due to Parathyroid hormone related protein (PTH-rP)
Serum PTH To check for cause of hypercalcemia. It helps to differentiate whether the high calcium level is due to hyperparathyroidism or paraneoplastic syndrome (PTH-rP)

Imaging Findings

  • There are three radiologic findings associated with bronchoalveolar carcinoma are:
  • The nodular form is the commonest and can not be differentiated from other adenocarcinoma subtypes on plain X-ray.
  • CT scan is imaging modality of the choice for bronchoalveolar carcinoma.
    • Non-Mucinous BAC: It appears as solid nodule surrounded by ground glass opacification- Fried egg sign
    • Mucinous BAC: It appears as single solid nodule

Bronchoalveolar carcinoma CT scan

  • Subtype of adenocarcinoma[1]
  • Single pulmonary nodule or mass
  • Multicentric or diffuse disease
  • Localized area of parenchymal consolidation
  • Bubble-like areas of low attenuation within the mass are a characteristic finding
  • Hilar and mediastinal lymphadenopathy is uncommon
  • Persistent peripheral consolidation with associated nodules

Other Diagnostic Studies

  • BAC may also be differentiated from invasive adenocarcinoma by using magnetic resonance imaging.
  • Image guided per-cutaneous fine needle aspiration biopsy or core biopsy can be used to get molecular characteristic of the tumor.
  • ECG can be done to rule out other causes of chest pain.

Treatment

Medical Therapy

Surgery

  • Surgery is the mainstay of therapy for bronchoalveolar carcinoma.
  • Pneumonectomy or lobectomy in conjunction with ipsilateral lymphadenectomy is the most common approach to the treatment of BAC.

Prevention

  • Effective measures for the primary prevention of Lung cancer include smoking cessation, avoid passive smoking, and taking precautionary measures to avoid exposure to harmful particles in work places.

See also, Lung cancer screening Lung Cancer Screening Decision Tool

References

  1. Gandara, David R.; Aberle, Denise; Lau, Derick; Jett, James; Akhurst, Tim; Mulshine, James; Berg, Christine; Patz, Edward F. (2006). "Radiographic Imaging of Bronchioloalveolar Carcinoma: Screening, Patterns of Presentation and Response Assessment". Journal of Thoracic Oncology. 1 (9): S20–S26. doi:10.1016/S1556-0864(15)30005-8. ISSN 1556-0864.